Response to Comments: MolDX: Breast Cancer IndexTM (BCI) Gene Expression Test

This record is a response-to-comments notice regarding the MolDX Breast Cancer Index (BCI) gene expression test; the comment period ran 10/04/2018–12/14/2018, the notice period ran 02/28/2019–04/15/2019, and the LCD became final on 04/16/2019. The document does not contain coverage criteria, limitations, or claim documentation requirements; users should consult LCD DL37824 for the final Medicare coverage policy and actionable clinical criteria.

"This document contains a response to comments for the MolDX Breast Cancer Index (BCI) gene expression test and does not specify clinical coverage criteria or claim documentation requirements; refer..."

Sign up to see full coverage criteria, indications, and limitations.